Overview

Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)

Status:
Active, not recruiting
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
Open-label, non-comparative, multicenter, phase II study of Vismodegib in patients with locally advanced BCC.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Lille
Collaborator:
Hoffmann-La Roche